Deaggregation of Human Platelets Aggregated by Thrombin

Summary

Human platelets that have undergone the release reaction do not deaggregate readily. We examined conditions under which washed human platelets can be deaggregated after they have undergone an extensive release reaction induced by thrombin (1 or 5 U/ml). To make fibrinogen receptors unavailable, either CP/ CPK (or apyrase) was used to remove released ADP, or PGEi was used to increase cAMP. Chymotrypsin was used to digest proteins that might link platelets, and heparin to interact with released proteins and interfere with their binding to platelets and to each other. Individually, none of these caused deaggregation; heparin did not inhibit the effect of thrombin because no antithrombin III was present. Platelets exposed to thrombin (1 U/ ml) which was neutralized at 90 sec by hirudin, could be deaggregated by combinations of CP/CPK (or apyrase) and chymotrypsin, or PGE₁ and chymotrypsin. When a higher concentration of thrombin was used (5 U/ml) these combinations caused platelets to deaggregate only when heparin was added before thrombin induced the release reaction. Thus, when extensive release occurs three mechanisms may come into play to link human platelets: one that requires the fibrinogen receptor; a heparin-sensitive reaction that may involve the binding of released proteins; and a linkage that can be disrupted only by proteolysis, providing the other two mechanisms are also inhibited.

Key words

Platelet deaggregation - Thrombin-induced aggregation - Release reaction

• References

• 1 Kinlough-Rathbone RL, Mustard JF, Perry DW, Dejana E, Cazenave J-P, Packham MA, Harfenist EJ. Factors influencing the deaggregation of human and rabbit platelets. Thromb Haemostas 1983; 49: 162-167
• 2 Mustard JF, Packham MA, Kinlough-Rathbone RL, Perry DW, Regoeczi E. Fibrinogen and ADP-induced platelet aggregation. Blood 1978; 52: 453-466
• 3 Hawiger J, Parkinson S, Timmons S. Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated platelets. Nature 1980; 283: 195-197
• 4 Mustard JF, Perry DW, Ardlie NG, Packham MA. Preparation of suspensions of washed platelets from humans. Br J Haematol 1972; 22: 193-204
• 5 Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. Harker LA, Zimmerman TS. (Eds) Methods in Hematology. Measurements of Platelet Function Churchill Livingstone; Edinburgh: 1983. pp 64-91
• 6 Greenberg J, Packham MA, Cazenave J-P, Reimers H-J, Mustard JF. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975; 32: 476-484
• 7 Nachman RL, Leung LL K. Complex formation of platelet membrane glycoproteins lib and Ilia with fibrinogen. J Clin Invest 1982; 69: 263-278
• 8 Harfenist EJ, Packham MA, Mustard JF. Reversibility of the association of fibrinogen with rabbit platelets exposed to ADP. Blood 1980; 56: 189-198
• 9 Harfenist EJ, Packham MA, Kinlough-Rathbone RL, Mustard JF. Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets, and cause rapid deaggregation and dissociation of bound fibrinogen. J Lab Clin Med 1981; 97: 680-688
• 10 Handin RI, Cohen HJ. Purification and binding properties of human platelet factor 4. J Biol Chem 1976; 251: 4273-4282
• 11 Phillips DR, Jennings LK, Prasanna HR. Ca²⁺-mediated association of glycoprotein G (thrombin-sensitive protein, thrombospondin) with human platelets. J Biol Chem 1980; 255: 11629-11632
• 12 Jaffe EA, Leung LL K, Nachman RL, Levin RI, Mosher DF. Thrombospondin is the endogenous lectin of human platelets. Nature 1982; 295: 246-248
• 13 Gartner TK, Dockter ME. Secreted platelet thrombospondin binds monovalently to platelets and erythrocytes in the absence of free Ca²⁺ . Thromb Res 1983; 33: 19-30
• 14 Ginsberg MH, Plow EF, Forsyth J. Fibronectin expression on the platelet surface occurs in concert with secretion. J Supramol Struct Cell Biochem 1981; 17: 91-98
• 15 Plow EF, Ginsberg MH. Specific and saturable binding of plasma fibronectin to thrombin-stimulated human platelets. J Biol Chem 1981; 256: 9477-9482
• 16 Ginsberg MH, Wencel JD, White JG, Plow EF. Binding of fibronectin to α-granule deficient platelets. J Cell Biol 1983; 97: 571-573
• 17 Leung LL, Harpel PC, Nachman RL, Rabellino EM. Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation. Blood 1983; 62: 1016-1021
• 18 Stathakis NE, Mosesson MW. Interactions among heparin, cold- insoluble globulin, and fibrinogen in formation of the heparin- precipitable fraction of plasma. J Clin Invest 1977; 60: 855-865
• 19 Lawler JW, Slayter HS, Coligan JW. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J Biol Chem 1978; 253: 8609-8616
• 20 Lijnen HR, van Hoef B, Collen D. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III. Thromb Haemostas 1983; 50: 560-562
• 21 Marshall SE, Luscombe M, Pepper DS, Holbrook JJ. The interaction of platelet factor 4 with heparins of different chain length. Biochim Biophys Acta 1984; 797: 34-39
• 22 Ciemiewski C, Switalska H, Hershock AM, Capitanio AM, Tuszynski GP, Niewiarowski S. Association of a granule proteins with platelet membranes and cytoskeletons. Fed Proc 1984; 43: 659
• 23 Lahav J, Schwartz MA, Hynes RO. Analysis of platelet adhesion with a radioactive chemical crosslinking reagent: interaction of thrombospondin with fibronectin and collagen. Cell 1982; 31: 253-262
• 24 Leung LL K, Nachman RL. Complex formation of platelet thrombospondin with fibrinogen. J Clin Invest 1982; 70: 542-549
• 25 Laudano AP, Doolittle RF. Synthetic peptide derivatives that bind to fibrinogen and prevent the polymerization of fibrin monomers. Proc Natl Acad Sci USA 1978; 75: 3085-3089